# Arine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arine

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.arine.io
- Total disclosed funding: $55M
- Latest round: Series C (May 2, 2025)
- Investors on record: 10

## About

Founded in 2017 and based in California, US, Arine, Inc. delivers AI-driven medication management solutions designed to enhance clinical outcomes and streamline healthcare costs for diverse populations. The company's innovative products enable organizations to optimize medication therapy management effectively.Arine, Inc. is focused on providing advanced medication management solutions through its AI technology. The founders, David de Vries and Yoona Kim, have previously made significant contributions to healthcare innovation. The headquarters is located in San Francisco, US. As of August 2022, Arine completed a Series B funding round, raising USD 18.50 mn, led by 111 West Capital, among other investors. The total amount raised by the company stands at USD 18.50 mn with a current valuation of USD 172.41 mn.Arine specializes in comprehensive medication management solutions powered by artificial intelligence (AI) aimed at improving clinical outcomes and reducing healthcare costs. The core offerings include the LUMINATE High-Risk Solution, RESONATE Prescriber Analytics, and ELEVATE Quality Improvement Medication Therapy Management. These products enable healthcare organizations to proactively identify and address medication-related issues for diverse populations, including Medicare, Medicaid, and commercial clients. By employing AI algorithms, Arine delivers tailored medication recommendations that account for clinical, behavioral, and social factors, facilitating improved patient engagement and care. The company serves a wide array of clients, including seven national health plans and two national pharmacy benefit managers (PBMs), impacting over 25 million lives across the United States.Arine operates primarily on a subscription-based revenue model, where healthcare organizations pay for access to its AI-powered medication management platform and associated services. Transactions typically involve partnerships with health plans and provider organizations, enabling clients to leverage Arine’s technology to enhance their medication therapy management capabilities. The company’s revenue is driven by the scalability of its platform, allowing clients to utilize the system for broad populations while achieving specific healthcare quality metrics. Among its flagship offerings, the proprietary capabilities of LUMINATE and ELEVATE are instrumental in generating value for clients, focusing on cost efficiency and improved patient outcomes, with a structured payment system aligned with contractual agreements established with various health plans and providers.In August 2022, Arine raised USD 29 mn in a Series B funding round to accelerate its platform's capabilities and increase offerings to channel partners across the value-based care continuum. The funding will support the development of new products designed to enhance medication intelligence and achieve improved health outcomes for clients. The company is also exploring expansion into new geographic regions to broaden its market reach, with specific targets to be outlined in upcoming strategic plans.

## Funding rounds

- Series C, May 2, 2025, $25M — Kaiser Permanente Ventures, Town Hall Ventures
- Series B, Jul 7, 2022, $19M — New Leaf Venture Partners, Katalyst Ventures, MBX Capital, 111 West Capital, Super Capital VC
- Series A, Oct 26, 2021, $11M — Magellan Health, Inc., Katalyst Ventures, Scan Health Plan, 111 West Capital
- Seed, Oct 4, 2019 — Katalyst Ventures
- Seed, May 15, 2019 — MaC Venture Capital
- Seed, Apr 17, 2019 — Katalyst Ventures

## Investors

- Katalyst Ventures — Seed, Series A, Series B
- MaC Venture Capital (https://capitalatlas.ai/funds/mac-venture-capital) — Seed
- Magellan Health, Inc. — Series A
- Scan Health Plan — Series A
- 111 West Capital (https://capitalatlas.ai/funds/111-west-capital) — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B
- MBX Capital (https://capitalatlas.ai/funds/mbx-capital) — Series B
- Super Capital VC (https://capitalatlas.ai/funds/super-capital-vc) — Series B
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series C
- Town Hall Ventures (https://capitalatlas.ai/funds/town-hall-ventures) — Series C